MiniMed expands board to 11 members

NORTHRIDGE, Calif. – MiniMed has announced that David Endicott and Linnea Burman have joined its board of directors, expanding the board from nine to 11 members. As MiniMed builds its next chapter as an independent company, Endicott, CEO of Alcon, adds experience scaling global health care businesses, leading through a public market separation and operating at board level in a large, regulated category, the company says. "David has done this before," said Que Dallara, CEO of MiniMed. "He brings decades of operating leadership across health care, deep public company experience, and firsthand knowledge of what it takes to lead through change and build for growth. That is especially valuable as MiniMed sharpens execution as an independent company." Medtronic plc, which continues to be the majority shareholder following MiniMed's separation and IPO earlier this year, has designated Burman to serve on the MiniMed board.

About Endicott: He joined Alcon in July 2016 as COO, was named CEO in July 2018, and led the company’s spin out and return to the public markets. Prior to joining Alcon, Endicott was president of Hospira Infusion Systems, a Pfizer company. Before joining Hospira, he served as an officer and executive committee member of Allergan, where he spent more than 25 years in leadership roles. He also currently serves on the board of AdvaMed.

About Burman: She is currently senior vice president and president, Neurovascular, at Medtronic. Across more than 19 years at the company, she has held a range of senior operating and strategic leadership roles, including vice president and general manager, Enabling Technologies, Cranial and Spinal Technologies, and vice president and general manager, Pelvic Health and Gastric Therapies.

Related reading:

• MiniMed launches Flex insulin pump in US.
• Medtronic’s MiniMed board sees shake up.